

Katsuyuki Hotta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2448024/publications.pdf>

Version: 2024-02-01

188
papers

18,092
citations

126907

33
h-index

13771

129
g-index

192
all docs

192
docs citations

192
times ranked

16103
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1823-1833. | 27.0 | 7,847 |
| 2 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830. | 13.7 | 2,347 |
| 3 | Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939. | 13.7 | 1,274 |
| 4 | Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. <i>Journal of Clinical Oncology</i> , 2019, 37, 537-546. | 1.6 | 1,144 |
| 5 | Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2017, 390, 29-39. | 13.7 | 753 |
| 6 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349. | 1.6 | 468 |
| 7 | Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3852-3859. | 1.6 | 373 |
| 8 | Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 51-65. | 10.7 | 356 |
| 9 | Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1600-1609. | 10.7 | 282 |
| 10 | Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: OLCSG 0007. <i>Journal of Clinical Oncology</i> , 2010, 28, 3299-3306. | 1.6 | 225 |
| 11 | Effect of gefitinib (Iressa™, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2004, 46, 255-261. | 2.0 | 175 |
| 12 | A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 273-279. | 1.1 | 119 |
| 13 | Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. <i>Cancer Research</i> , 2016, 76, 1506-1516. | 0.9 | 115 |
| 14 | Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 195-199. | 2.0 | 100 |
| 15 | Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience. <i>Journal of Thoracic Oncology</i> , 2010, 5, 179-184. | 1.1 | 69 |
| 16 | Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Receiving Gefitinib. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 417-424. | 2.0 | 68 |
| 17 | The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 140-145. | 2.0 | 68 |
| 18 | Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials. <i>Journal of Thoracic Oncology</i> , 2007, 2, 402-407. | 1.1 | 67 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705. <i>Journal of Thoracic Oncology</i> , 2010, 5, 99-104. | 1.1 | 67 |
| 20 | Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review. <i>PLoS ONE</i> , 2011, 6, e26646. | 2.5 | 66 |
| 21 | Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 632-637. | 1.1 | 62 |
| 22 | Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive <i>ALK</i>-positive non-small cell lung cancer (<i>ALK+</i> NSCLC): Primary results from the J-ALEX study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9008-9008. | 1.6 | 58 |
| 23 | Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 311-317. | 1.1 | 55 |
| 24 | Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 477-482. | 1.1 | 49 |
| 25 | Reappraisal of Short-term Low-volume Hydration in Cisplatin-based Chemotherapy: Results of a Prospective Feasibility Study in Advanced Lung Cancer in the Okayama Lung Cancer Study Group Trial 1002. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 1115-1123. | 1.3 | 48 |
| 26 | Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. <i>Cancer</i> , 2007, 109, 939-948. | 4.1 | 44 |
| 27 | The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 762-765. | 1.3 | 43 |
| 28 | Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9000-9000. | 1.6 | 43 |
| 29 | Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: <sc>ASCEND</sc>. <i>Cancer Science</i> , 2018, 109, 2863-2872. | 3.9 | 42 |
| 30 | Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 20-26. | 2.0 | 39 |
| 31 | Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9002-9002. | 1.6 | 36 |
| 32 | Long-Standing Debate on Cisplatin- Versus Carboplatin-Based Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 96. | 1.1 | 35 |
| 33 | MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. <i>Scientific Reports</i> , 2018, 8, 1955. | 3.3 | 34 |
| 34 | The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. <i>European Journal of Cancer</i> , 2021, 149, 73-81. | 2.8 | 34 |
| 35 | A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 162, 140-146. | 2.0 | 32 |
| 36 | An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2004, 46, 61-76. | 2.0 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501. <i>Lung Cancer</i> , 2015, 87, 141-147. | 2.0 | 30 |
| 38 | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. <i>Lung Cancer</i> , 2019, 129, 55-62. | 2.0 | 29 |
| 39 | VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small cell lung cancers. <i>Cancer Science</i> , 2021, 112, 1853-1864. | 3.9 | 29 |
| 40 | Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2013, 81, 435-439. | 2.0 | 28 |
| 41 | Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 249-256. | 1.8 | 28 |
| 42 | Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. <i>Lung Cancer</i> , 2020, 149, 46-52. | 2.0 | 28 |
| 43 | Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 29525-29531. | 1.8 | 28 |
| 44 | Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. <i>Cancer Science</i> , 2018, 109, 3921-3933. | 3.9 | 27 |
| 45 | Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. <i>Clinical Lung Cancer</i> , 2018, 19, e861-e864. | 2.6 | 27 |
| 46 | Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. <i>International Journal of Clinical Oncology</i> , 2016, 21, 81-87. | 2.2 | 26 |
| 47 | Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma. , 2020, 8, e000461. | | 26 |
| 48 | Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 101-106. | 4.2 | 26 |
| 49 | A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. <i>Lung Cancer</i> , 2018, 115, 103-108. | 2.0 | 25 |
| 50 | Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab. <i>Internal Medicine</i> , 2019, 58, 985-989. | 0.7 | 25 |
| 51 | A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). <i>Chest</i> , 2019, 156, 357-366. | 0.8 | 25 |
| 52 | A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 699-706. | 1.1 | 24 |
| 53 | A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol. <i>Clinical Lung Cancer</i> , 2018, 19, e705-e707. | 2.6 | 23 |
| 54 | Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. <i>Oncology Reports</i> , 2007, 17, 313-7. | 2.6 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2009-2018. | 1.1 | 22 |
| 56 | Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. <i>Cancer Science</i> , 2018, 109, 3149-3158. | 3.9 | 20 |
| 57 | Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status. <i>Cancer Science</i> , 2020, 111, 3739-3746. | 3.9 | 20 |
| 58 | Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group Experience. <i>Acta Oncologica</i> , 2005, 44, 717-722. | 1.8 | 19 |
| 59 | Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. <i>Clinical Lung Cancer</i> , 2017, 18, 92-95. | 2.6 | 19 |
| 60 | Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, 134-138. | 2.6 | 19 |
| 61 | Desire for Information and Involvement in Treatment Decisions: Lung Cancer Patients' Preferences and Their Physicians' Perceptions: Results from Okayama Lung Cancer Study Group Trial 0705. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1668-1672. | 1.1 | 18 |
| 62 | A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0801. <i>European Journal of Cancer</i> , 2014, 50, 2783-2790. | 2.8 | 18 |
| 63 | Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy. <i>Molecular and Clinical Oncology</i> , 2015, 3, 706-712. | 1.0 | 18 |
| 64 | Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung Cancer. <i>Respiratory Investigation</i> , 2015, 53, 93-97. | 1.8 | 18 |
| 65 | Pembrolizumab for the first-line treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1015-1021. | 3.1 | 18 |
| 66 | Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 871-874. | 1.3 | 17 |
| 67 | Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 458-464. | 1.3 | 17 |
| 68 | Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121211. | 2.5 | 16 |
| 69 | Pharmacologic study (JCO28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy. <i>Cancer Science</i> , 2016, 107, 1642-1646. | 3.9 | 15 |
| 70 | Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 360-367. | 2.1 | 15 |
| 71 | Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 54-58. | 2.0 | 15 |
| 72 | Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100107. | 1.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Downregulation of TBXAS 1 in an iron-induced malignant mesothelioma model. <i>Cancer Science</i> , 2015, 106, 1296-1302. | 3.9 | 14 |
| 74 | Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1005-1009. | 2.3 | 14 |
| 75 | Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M. <i>Molecular Oncology</i> , 2017, 11, 670-681. | 4.6 | 14 |
| 76 | Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1447-1453. | 1.3 | 14 |
| 77 | Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK+ fusion positive non-small cell lung cancer (ALK+ NSCLC). <i>Journal of Clinical Oncology</i> , 2017, 35, 9064-9064. | 1.6 | 14 |
| 78 | Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. <i>Clinical Lung Cancer</i> , 2016, 17, 75-79. | 2.6 | 13 |
| 79 | Rapid on-site evaluation with BIOEVALUATOR during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing pulmonary and mediastinal diseases. <i>Annals of Thoracic Medicine</i> , 2014, 9, 14. | 1.8 | 12 |
| 80 | Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 603-4. | 1.3 | 12 |
| 81 | Pilot evaluation of a HER2 testing in non-small-cell lung cancer. <i>Journal of Clinical Pathology</i> , 2020, 73, 353-357. | 2.0 | 12 |
| 82 | A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 963-968. | 1.3 | 11 |
| 83 | Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 251-256. | 2.3 | 11 |
| 84 | PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024. <i>Journal of Thoracic Oncology</i> , 2017, 12, S8-S9. | 1.1 | 11 |
| 85 | Nivolumab for the treatment of unresectable pleural mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 109-114. | 3.1 | 11 |
| 86 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. <i>International Journal of Clinical Oncology</i> , 2022, 27, 695-706. | 2.2 | 11 |
| 87 | Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). <i>Clinical Lung Cancer</i> , 2016, 17, 602-605. | 2.6 | 10 |
| 88 | Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2020, 532, 341-346. | 2.1 | 10 |
| 89 | First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes. <i>Journal of Clinical Oncology</i> , 2020, 38, 9068-9068. | 1.6 | 10 |
| 90 | CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in EGFR-Mutant Lung Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 1111-1126. | 3.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: Results from a prospective feasibility study. <i>Lung Cancer</i> , 2005, 50, 413-415. | 2.0 | 9 |
| 92 | Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2008, 62, 236-241. | 2.0 | 9 |
| 93 | Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. <i>Clinical Lung Cancer</i> , 2017, 18, 241-244. | 2.6 | 9 |
| 94 | Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 100-103. | 2.6 | 9 |
| 95 | Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review. <i>Internal Medicine</i> , 2020, 59, 823-828. | 0.7 | 9 |
| 96 | Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. <i>Lung Cancer</i> , 2020, 150, 83-89. | 2.0 | 9 |
| 97 | First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1073-1082. | 2.2 | 9 |
| 98 | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. , 2021, 9, e003288. | | 9 |
| 99 | Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. <i>Current Opinion in Oncology</i> , 2006, 18, 144-150. | 2.4 | 8 |
| 100 | Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. <i>Lung Cancer</i> , 2010, 70, 308-312. | 2.0 | 8 |
| 101 | Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 943-950. | 2.3 | 8 |
| 102 | Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 741-747. | 1.3 | 8 |
| 103 | Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. <i>Clinical Lung Cancer</i> , 2017, 18, 245-249. | 2.6 | 8 |
| 104 | Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study. <i>BMC Cancer</i> , 2018, 18, 350. | 2.6 | 8 |
| 105 | Identification of targetable kinases in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, 20. | 3.6 | 8 |
| 106 | Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 117-123. | 2.5 | 7 |
| 107 | A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 769-774. | 2.3 | 7 |
| 108 | The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy. <i>Annals of Thoracic Surgery</i> , 2016, 102, 985-992. | 1.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. <i>Internal Medicine</i> , 2019, 58, 3033-3037. | 0.7 | 7 |
| 110 | EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice. <i>Lung Cancer</i> , 2019, 136, 86-93. | 2.0 | 7 |
| 111 | Physician requests by patients with malignant pleural mesothelioma in Japan. <i>BMC Cancer</i> , 2019, 19, 383. | 2.6 | 7 |
| 112 | Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 461-467. | 2.2 | 7 |
| 113 | Impact of previous thoracic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 279-286. | 1.3 | 7 |
| 114 | Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 101-108. | 1.1 | 7 |
| 115 | A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations. <i>Lung Cancer</i> , 2021, 156, 1-4. | 2.0 | 7 |
| 116 | SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1653-1662. | 4.1 | 7 |
| 117 | Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1269-1276. | 1.3 | 7 |
| 118 | Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting. <i>Anticancer Research</i> , 2017, 37, 1507-1514. | 1.1 | 7 |
| 119 | Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSCG 1801. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1139-1144. | 2.2 | 7 |
| 120 | Cure- or Care-Oriented Regimen for Stage III Non-Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , 2011, 29, e320-e320. | 1.6 | 6 |
| 121 | Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 941-947. | 2.3 | 6 |
| 122 | Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 434-437. | 1.3 | 6 |
| 123 | Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3749-3755. | 2.5 | 6 |
| 124 | A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 956-965. | 1.3 | 6 |
| 125 | First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset*. <i>Cancer Science</i> , 2021, 112, 5000-5010. | 3.9 | 6 |
| 126 | Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. <i>Journal of Clinical Oncology</i> , 2014, 32, 8103-8103. | 1.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 755-760. | 2.3 | 5 |
| 128 | Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy. <i>Lung Cancer</i> , 2007, 55, 343-348. | 2.0 | 5 |
| 129 | Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 993-999. | 2.4 | 5 |
| 130 | Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin. <i>Annals of Thoracic Surgery</i> , 2017, 104, 971-978. | 1.3 | 5 |
| 131 | A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. <i>Lung Cancer</i> , 2017, 112, 188-194. | 2.0 | 5 |
| 132 | Recent trends in the treatment of unresectable stage III non-small-cell lung cancer. <i>Respiratory Investigation</i> , 2019, 57, 330-336. | 1.8 | 5 |
| 133 | Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. <i>International Journal of Clinical Oncology</i> , 2019, 24, 41-45. | 2.2 | 5 |
| 134 | Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study. <i>BMC Geriatrics</i> , 2021, 21, 74. | 2.7 | 5 |
| 135 | Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. <i>Thoracic Cancer</i> , 2021, 12, 643-649. | 1.9 | 5 |
| 136 | First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1869-1877. | 2.5 | 5 |
| 137 | A Survey of Japanese Thoracic Oncologists' Perception of Diagnostic and Treatment Strategies for EGFR Mutant or EML4-ALK Fusion Non-small Cell Lung Cancer. <i>Chest</i> , 2014, 146, e222-e225. | 0.8 | 4 |
| 138 | Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation. <i>OncoTargets and Therapy</i> , 2016, 9, 1753. | 2.0 | 4 |
| 139 | Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 3076-3086. | 1.4 | 4 |
| 140 | Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1367-1376. | 2.2 | 4 |
| 141 | An Evaluation of the Safety and Feasibility of Adenosine-assisted Clipping Surgery for Unruptured Cerebral Aneurysms: Study Protocol. <i>Neurologia Medico-Chirurgica</i> , 2021, 61, 393-396. | 2.2 | 4 |
| 142 | Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction. <i>Oncology Letters</i> , 2020, 20, 1-1. | 1.8 | 4 |
| 143 | Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2401. | 4.3 | 3 |
| 144 | Current status and future perspectives of cooperative study groups for lung cancer in Japan. <i>Respiratory Investigation</i> , 2014, 52, 339-347. | 1.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 287-290. | 1.3 | 3 |
| 146 | Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib. <i>Internal Medicine</i> , 2019, 58, 1625-1627. | 0.7 | 3 |
| 147 | A phase I/II trial of weekly nab-paclitaxel for pretreated non-small cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 250-256. | 1.1 | 3 |
| 148 | Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. <i>Respiratory Investigation</i> , 2021, 59, 240-246. | 1.8 | 3 |
| 149 | Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301. <i>BMC Cancer</i> , 2021, 21, 506. | 2.6 | 3 |
| 150 | Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer. <i>Anticancer Research</i> , 2007, 27, 1737-41. | 1.1 | 3 |
| 151 | Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 529-533. | 1.3 | 2 |
| 152 | Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2018, 24, 131-138. | 0.8 | 2 |
| 153 | Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. <i>Respiratory Investigation</i> , 2019, 57, 460-465. | 1.8 | 2 |
| 154 | Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. <i>Acta Oncologica</i> , 2020, 59, 324-328. | 1.8 | 2 |
| 155 | Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS Lung study protocol. <i>Thoracic Cancer</i> , 2021, 12, 725-731. | 1.9 | 2 |
| 156 | A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902/OLCSG0905 intergroup trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7045-7045. | 1.6 | 2 |
| 157 | Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9038-9038. | 1.6 | 2 |
| 158 | Three doses of mRNA COVID-19 vaccine protects from SARS-CoV-2 infections in Japan. <i>Journal of Internal Medicine</i> , 2022, 292, 687-689. | 6.0 | 2 |
| 159 | Author reply to recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. <i>Cancer</i> , 2007, 110, 2594-2594. | 4.1 | 1 |
| 160 | A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization. <i>Acta Oncologica</i> , 2009, 48, 471-473. | 1.8 | 1 |
| 161 | Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan. <i>Internal Medicine</i> , 2022, 61, 379-383. | 0.7 | 1 |
| 162 | Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF1/TGF α expression. <i>Oncology Letters</i> , 2021, 22, 639. | 1.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation.. Journal of Clinical Oncology, 2012, 30, 2607-2607. | 1.6 | 1 |
| 164 | Impact of concomitant use of anti-acid agents on efficacy of gefitinib in EGFR-mutant non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19008-e19008. | 1.6 | 1 |
| 165 | Phase II study of topotecan and cisplatin with sequential radiotherapy in elderly small cell lung cancer patients (Okayama Lung Cancer Study Group; OLCSG 0102).. Journal of Clinical Oncology, 2015, 33, 7572-7572. | 1.6 | 1 |
| 166 | Development of skin rash within the 1st week is a potential surrogate marker of therapeutic effect in afatinib monotherapy in patients with EGFR-mt non-small-cell lung cancer (NSCLC): Okayama Lung Cancer Study Group Experience.. Journal of Clinical Oncology, 2015, 33, e19051-e19051. | 1.6 | 1 |
| 167 | A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy. Okayama Igakukai Zasshi, 2015, 127, 127-132. | 0.0 | 1 |
| 168 | Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report. Case Reports in Oncology, 2022, 15, 494-498. | 0.7 | 1 |
| 169 | A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401. Supportive Care in Cancer, 2021, 29, 5237-5244. | 2.2 | 0 |
| 170 | Classification and Treatment of Oligometastatic Disease in Non-Small-Cell Lung Cancer. Japanese Journal of Lung Cancer, 2021, 61, 95-99. | 0.1 | 0 |
| 171 | Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.. Journal of Clinical Oncology, 2021, 39, e20590-e20590. | 1.6 | 0 |
| 172 | Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. European Journal of Cancer, 2021, 157, 523-524. | 2.8 | 0 |
| 173 | Survival post-progression (SPP) in phase III trials of chemotherapy in advanced NSCLC: Its potentially different impact on OS in the first-line and salvage settings.. Journal of Clinical Oncology, 2012, 30, e18027-e18027. | 1.6 | 0 |
| 174 | Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience.. Journal of Clinical Oncology, 2012, 30, 7576-7576. | 1.6 | 0 |
| 175 | Impact of body surface area (BSA) on efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19167-e19167. | 1.6 | 0 |
| 176 | Survival analysis of induction cisplatin (CDDP)-docetaxel (DOC)-bevacizumab (BEV) chemotherapy followed by maintenance BEV-pemetrexed (PEM) therapy in advanced nonsquamous non-small cell lung cancer (NonSq NSCLC): A phase II trial from Okayama Lung Cancer Study Group 0903.. Journal of Clinical Oncology, 2013, 31, e19040-e19040. | 1.6 | 0 |
| 177 | Prospective cohort study of serum sialylated glycoprotein (KL-6) as a prognostic marker in patients (pts) with non-small cell lung cancer (NSCLC) receiving gefitinib monotherapy: Okayama Lung Cancer Study Group 0703.. Journal of Clinical Oncology, 2013, 31, e19023-e19023. | 1.6 | 0 |
| 178 | A survey on Japanese thoracic oncologists'™ preference on treatment strategy for EGFR-mutant or EML4-ALK-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19124-e19124. | 1.6 | 0 |
| 179 | Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.. Journal of Clinical Oncology, 2014, 32, e19102-e19102. | 1.6 | 0 |
| 180 | Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.. Journal of Clinical Oncology, 2014, 32, e19084-e19084. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | A phase II study of S-1 and concurrent thoracic radiotherapy (TRT) for elderly pts with locally advanced non-small cell lung cancer (LA-NSCLC): Okayama Lung Cancer Study Group trial 0801.. Journal of Clinical Oncology, 2014, 32, 7576-7576. | 1.6 | 0 |
| 182 | Publication of Lung Cancer Clinical Trials in Japan. Japanese Journal of Lung Cancer, 2015, 55, 1070-1074. | 0.1 | 0 |
| 183 | Three-arm randomized trial of sodium alginate, orally administered mucoprotective agent, for preventing radiation esophagitis in pts with locally advanced non-small-cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT): Okayama Lung Cancer Study Group 1401.. Journal of Clinical Oncology, 2015, 33, TPS9641-TPS9641. | 1.6 | 0 |
| 184 | Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.. Journal of Clinical Oncology, 2016, 34, 10100-10100. | 1.6 | 0 |
| 185 | Clinical features of squamous cell lung cancer with targetable gene alterations in a nationwide genomic screening network in Japan (LC-SCRUM-Japan).. Journal of Clinical Oncology, 2017, 35, 9057-9057. | 1.6 | 0 |
| 186 | Revision of Lung Cancer Clinical Practice Guidelines -Focusing on the Area of Pharmacotherapy-. Japanese Journal of Lung Cancer, 2019, 59, 1076-1078. | 0.1 | 0 |
| 187 | Revision of Lung Cancer Clinical Practice Guidelines -Focusing on the Area of Pharmacotherapy-. Japanese Journal of Lung Cancer, 2020, 60, 910-912. | 0.1 | 0 |
| 188 | Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study.. Journal of Clinical Oncology, 2022, 40, TPS12141-TPS12141. | 1.6 | 0 |